The cell counting market size is estimated to be USD 7,845.3 million in 2022 and is expected to witness a CAGR of 8.82% during the forecast period 2023-2033. Rising demand for biologics for the treatment of chronic diseases, increasing prevalence of target diseases like HIV, measles, diphtheria, and chronic diseases such as cancer and other blood disorders and surge in usage of automated haematology analyzers and high-throughput flow cytometry are factors contributing to the market growth. Furthermore, government programmes to support cell therapies research and technical developments in the devices is expected support the market growth. However, high price of cell analysis is expected to hinder the growth.

Government programmes to support cell therapies research is expected to propel the market growth. Additionally, recent increases in financing for stem cell research have further expedited the field’s expansion. For instance, the California Institute for Regenerative Medicine provided funding of USD 5 million in September 2021 for the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCLA.

Technical developments in the devices is projected to fuel the market. For instance, Merck launched Scepter 3.0, an automated handheld cell counting, in December 2020. Scepter 3.0 has a high degree of accuracy and can count hundreds of cells per measurement. The automated CytoSMART Exact FL, the company’s first fluorescent cell counter, was released in April 2021 by CytoSMART Technologies. It is a dual-fluorescence instrument used in typical laboratory settings. Similar to this, DeNovix introduced the first imaging cell counter in June 2020, eliminating deal with the need for slides and reducing the laboratory’s impact on the environment.

Segmentation

By Product

The market is categorized into consumables & accessories and instruments. In 2022, the consumables & accessories accounted for the highest revenue share due to their increasing usage volume. Reagents, microplates, magnetic beads, and chamber slides are some of the consumables and accessories used with these devices. Additionally, the introduction of new products spurs market expansion. For instance, eNuvio launched a reusable 3D cell culture microplate in December 2020. This advanced plate enables researchers to create embryoid bodies, which are a prerequisite for growing larger organoids or spheroids from stem cells. According to eNuvio, scientists will gain from this eco-friendly tool for a very long time in both an economic and scientific aspect.

By Application

The market is categorized into stem cell research, complete blood count, toxicology, cell-based therapeutics, and others. In the global market, the complete blood count segment accounted for the largest revenue share in 2022 owing to the fact that it is one of the most popular procedures for determining a person’s general health. The test measures a number of blood constituents, including RBC, WBC, haemoglobin, hematocrit, and platelets. As complete blood counts are frequently used to monitor such diseases, rising frequency of blood disorders such anaemia and leukaemia is expected to spur segment expansion.

By End User

The market is segmented into research & academic institutes, hospital & diagnostic laboratories, pharmaceutical & biotechnology companies, and others. In 2022, the research & academic institutes segment accounted for the largest revenue share owing to widespread use of cytometers in cell biology research activities. Researchers use cytometers to measure criteria including physical characteristics, type, and lineage in order to track the progress of viruses, diseases, and other bacteria. The segment is further driven by strategic actions taken by major market participants. For instance, Alliance Global set up an Automated Cell Counter system at the United Arab Emirates University in Al Ain in March 2021.

Regional Markets

In 2022, North America region accounted for the highest revenue in the cell counting market and is expected to maintain its dominance during the forecast period. This is attributed to the growing emphasis on biomedical and cancer research. One of the key factors influencing the use of these devices is the increase in the incidence of chronic diseases, such as blood and cardiovascular disorders. According to the American National Red Cross, 90,000 to 100,000 Americans are affected by sickle cell disease. Asia Pacific is anticipated to grow exponentially during the predicted period. This region’s concentration of clinical research and biopharmaceutical businesses can be responsible for the exponential CAGR. In addition, the region’s market is primarily being driven by the increasing geriatric population, which is extremely sensitive to chronic diseases.

Competitor Insights

Some of the key players operating in the cell counting market are Merck KGaA, Danaher, BD, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., BioTek Instruments, Inc., Agilent Technologies, GE Healthcare, and DeNovix Inc.

To increase their market position, key companies in this market are implementing several strategies into practise, such as alliances formed through mergers and acquisitions, geographic expansions, and strategic collaborations.

• For instance, PerkinElmer announced in May 2021 that it had acquired Nexcelom Bioscience, expanding its Cell biology expertise. With the acquisition, PerkinElmer gains access to the cell counting product line from Nexcelom Bioscience and expands its QA/QC capacities.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Cell Counting Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Consumables & Accessories
  • Microplates
  • Reagents
  • Others
• Instruments
  • Flow Cytometers
  • Microscopes
  • Automated Cell Counters
  • Haemocytometers
  • Spectrophotometers
  • Others

Application (Revenue, USD Million), 2022 – 2033

• Stem Cell Research
• Complete Blood Count
  • Manual Cell Counters
  • Automated Cell Counters
• Toxicology
• Cell Based Therapeutics
• Others

End user (Revenue, USD Million), 2022 – 2033

• Research & Academic Institutes
• Hospital & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA